Precision Medicine Companion Diagnostic (CDx)
Phoenix Molecular Designs partnered with Roche to develop a companion diagnostic (CDx) in parallel with our novel therapeutic for cancer.
Our diagnostic assay is a simple and inexpensive immunohistochemistry (IHC) test that stains tumor tissue for activated RSK2. This test will identify patients who will benefit most from our small molecule RSK kinase inhibitor, PMD-026.
Preliminary data indicates that 70% of metastatic stage 4 breast cancer cases express activated RSK2 including metastases. More broadly, an investigation of 600 biopsies revealed that RSK2 is activated in 79 percent of tumors from a study of 14 different tumor types.
Together, our drug and CDx will greatly improve outcomes for patients by accelerating their path to treatment.